Media Coverage

FDA approves Spravato nasal spray for depression

Mar 6, 2019

BioSpace's Global Biopharma Roundup: February 21

Feb 21, 2019

J&J nears FDA approval for landmark depression drug to replace ketamine treatments

Feb 13, 2019

Can We Treat Mood Disorders With Pharmacological Therapeutics?

Feb 1, 2019

Exclusive Interview: VistaGen CEO Is Passionate About Developing New Treatments for Depression

Jan 16, 2019

VistaGen CEO notes broad market potential of ketamine-like AV-101

Nov 26, 2018

Health Care Digest: A small biotech goes head first, Gilead's lower tax rate and more

Oct 29, 2018

Company focus: VistaGen

Oct 22, 2018

VistaGen acquires worldwide license of phase 3-ready CNS drug

Oct 1, 2018

VistaGen nabs phase 3-ready social anxiety drug from Pherin

Sep 13, 2018

• « Previous
• 1
• 2
• 3
• Next »